In the flow: A key acquisition, new blood-analyzing tech and critical Medicare/Medicaid reimbursements for T-cell therapies have Applied DNA Sciences and 2018 spinoff LineaRX pumped up.
AUGUST 12, 2019
By GREGORY ZELLER //
Just 11 months after spinning off from its parent company, a Stony Brook startup with expansion in its DNA has made its first corporate acquisition.
LineaRX, a subsidiary of Applied DNA Sciences, has acquired the physical assets and intellectual property of Vitatex Inc., a private biotech with close ties to Stony Brook University and a patented method of isolating Invasive Circulating Tumor Cells in standard blood samples – spotting metastatic cells before primary tumors are usually visible, allowing for a range of preventative-care options.
